Premium
NEW FINDINGS IN APPARENT MINERALOCORTICOID EXCESS
Author(s) -
DIMARTINONARDI J.,
STONER E.,
MARTIN K.,
BALFE J. W.,
JOSE P. A.,
NEW M. I.
Publication year - 1987
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1987.tb00838.x
Subject(s) - endocrinology , medicine , mineralocorticoid , hypoaldosteronism , spironolactone , cortisone , plasma renin activity , aldosterone , hydrocortisone , blood pressure , hyperkalemia , chemistry , renin–angiotensin system
SUMMARY We report two female siblings (ages 4 and 9 years) and one 8‐year‐old male with the syndrome of apparent mineralocorticoid excess (AME) presenting with low renin hypertension and hypoaldosteronism. The deficiency of 11β‐hydroxysteroid dehydrogenase results in a defect of the peripheral metabolism of Cortisol (F) to cortisone (E). As a result, the serum Cortisol half‐life (T½) is prolonged, ACTH is suppressed, and serum F is normal. The specific diagnosis of the disorder was made by the decreased ratio of the urinary metabolites of E (tetrahydrocortisone, THE) and F (tetrahydrocortisol, THF). Continuous i.v. hydrocortisone administration caused an increase in blood pressure and decrease in serum potassium demonstrating the abnormal mineralocorticoid activity of Cortisol in these patients. Addition of spironolactone resulted in a decrease in blood pressure, rise in serum potassium and a gradual increase in plasma renin activity. These studies suggest that an abnormality in Cortisol action or metabolism results in Cortisol behaving as a potent mineralocorticoid and causing the syndrome of AME.